BMC Endocrine Disorders (Jan 2019)

11β Hydroxysteroid dehydrogenase – 1 activity in type 2 diabetes mellitus: a comparative study

  • Ravindra Shukla,
  • Asish Kumar Basu,
  • Biplab Mandal,
  • Pradip Mukhopadhyay,
  • Animesh Maity,
  • Satyam Chakraborty,
  • Praveen Kumar Devrabhai

DOI
https://doi.org/10.1186/s12902-019-0344-9
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background A comparative study of 11 β HSD 1 activity in type 2 diabetes mellitus subjects with respect to fasting blood glucose and other metabolic parameters was conducted. Methods A case control experimental study was performed enrolling thirty type 2 diabetes mellitus patients and thirty age, gender and BMI matched controls using cortisone acetate test. Results The rise of serum cortisol after oral 25 mg cortisone acetate from baseline (dexamethasone suppressed level) is higher in subjects with type 2 diabetes and is associated with exercise, BMI, SGOT but not daily calorie intake, lipid parameters and thyroid status. Fasting blood glucose after overnight 1 mg oral dexamethasone is a strong predictor of 11HSD1 activity, irrespective of presence of type 2 diabetes. Conclusion 11β HSD 1 activity is higher in type 2 diabetes mellitus subjects, especially those who are lean. Future 11 β HSD 1 inhibitors targeting metabolic syndrome, will be most useful in those with increased fasting blood glucose. The role of DHEAS and vitamin D status needs to be explored.

Keywords